Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 1 038.4 USD 0.53% Market Closed
Market Cap: 981.7B USD

Intrinsic Value

The intrinsic value of one LLY stock under the Base Case scenario is 408.77 USD. Compared to the current market price of 1 038.4 USD, Eli Lilly and Co is Overvalued by 61%.

LLY Intrinsic Value
408.77 USD
Overvaluation 61%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Eli Lilly and Co

What is Valuation History?
Ask AI Assistant
What other research platforms think about LLY?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is LLY valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Eli Lilly and Co.

Explain Valuation
Compare LLY to
Custom
Choose any stock to compare

Fundamental Analysis

LLY Profitability Score
Profitability Due Diligence

Loading...
Loading...
Loading...
Loading...
Profitability
Score

LLY Solvency Score
Solvency Due Diligence

Loading...
Loading...
Loading...
Loading...
Solvency
Score
Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Despite the significant buzz around tirzepatide and other diabetes products, their high development and marketing costs could erode profitability if insurance reimbursement or pricing pressures intensify, particularly in today’s cost-conscious healthcare environment.

Eli Lilly’s reliance on blockbuster treatments like Trulicity exposes it to heightened competitive threats and patent cliffs—any new biosimilar entrants or patent challenges could substantially reduce revenue streams faster than anticipated.

R&D setbacks in the high-risk neurology and oncology segments could stall the pipeline’s momentum, especially if trials fail to demonstrate clear clinical benefits, jeopardizing future growth and investor confidence.

Bull Theses

Tirzepatide’s rapid approvals and robust clinical outcomes in diabetes and obesity treatments position Eli Lilly to capture valuable market share in a high-growth therapeutic area, protecting long-term revenue streams.

A well-diversified pipeline, including Alzheimer’s candidates like donanemab, aligns with major unmet clinical needs and underscores Eli Lilly’s capacity to deliver innovative treatments that command premium pricing.

The company’s strategic partnerships and acquisitions, such as those aimed at expanding the oncology platform, strengthen its pipeline while distributing R&D risk across multiple promising therapeutic classes.

Show More Less
How do you feel about LLY?
Bearish
Neutral
Bullish
Efficiency

Free Cash Flow Analysis
Eli Lilly and Co

Last Value
3-Years Average
FCF Margin
Conversion Rate

Wall St
Price Targets

LLY Price Targets Summary
Eli Lilly and Co

Wall Street analysts forecast LLY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LLY is 1 129.89 USD with a low forecast of 713.1 USD and a high forecast of 1 575 USD.

Lowest
Price Target
713.1 USD
31% Downside
Average
Price Target
1 129.89 USD
9% Upside
Highest
Price Target
1 575 USD
52% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Previous Payment
-
Today
Next Payment
-
Today
Jan 19, 2026
Previous Payment
-
Next Payment
-
Ex-Dividend Date
-
Shareholder Yield

Current shareholder yield for LLY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

LLY Insider Trading
Buy and sell transactions by insiders

LLY News

Other Videos
What is the Intrinsic Value of one LLY stock?

The intrinsic value of one LLY stock under the Base Case scenario is 408.77 USD.

Is LLY stock undervalued or overvalued?

Compared to the current market price of 1 038.4 USD, Eli Lilly and Co is Overvalued by 61%.

Back to Top